Modality
ASO
MOA
TYK2i
Target
BET
Pathway
Proteasome
CKDADPKD
Development Pipeline
Preclinical
~Jul 2012
→ ~Oct 2013
Phase 1
~Jan 2014
→ ~Apr 2015
Phase 2
~Jul 2015
→ ~Oct 2016
Phase 3
~Jan 2017
→ ~Apr 2018
NDA/BLA
~Jul 2018
→ ~Oct 2019
Approved
Jan 2020
→ Dec 2029
ApprovedCurrent
NCT07416759
1,693 pts·CKD
2020-01→2025-08·Terminated
NCT07836225
202 pts·CKD
2024-08→2029-12·Active
NCT03037742
1,987 pts·ADPKD
2020-06→2025-12·Not yet recruiting
3,882 total pts2 indications
CompletedCurrentUpcoming
Catalysts (3)
2025-08-098mo agoPh3 Readout· CKD
2025-12-114mo agoPh3 Readout· ADPKD
2029-12-073.7y awayPh3 Readout· CKD
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
Approved
Termina…
Approved
Not yet…
Approved
Active
Catalysts
Ph3 Readout
2025-08-09 · 8mo ago
CKD
Ph3 Readout
2025-12-11 · 4mo ago
ADPKD
Ph3 Readout
2029-12-07 · 3.7y away
CKD
ActiveTerminatedNot yet recruiting|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07416759 | Approved | CKD | Terminated | 1693 | DOR |
| NCT07836225 | Approved | CKD | Active | 202 | OS |
| NCT03037742 | Approved | ADPKD | Not yet recr... | 1987 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| MRK-2473 | Merck & Co | Phase 1/2 | Nectin-4 | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Voxacagene | Gilead Sciences | Phase 2/3 | SOS1 |